Monitor the ASH presentation on December 12, 2026 for any clinical response rates or survival data that could inform the registrational path. The current data are mechanistic and do not change the near-term outlook.
Drug in focus
ONCY drug pipeline →pelareorep
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2/3
- Time to market
- At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
- Next catalyst
- None dated
What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $0.4077entry
- T+1 · 7d ago −6.35%α −5.98% · $0.3818
- T+5 · 20h ago −16.63%α −14.94% · $0.3399
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech announced translational data from a Phase 1b/2 trial of pelareorep in heavily pretreated relapsed/refractory multiple myeloma, to be presented at the ASH annual meeting. The data show immune activation and direct tumor effects, but this is an early-stage, non-regulatory update with no new clinical endpoints or financial guidance.
Key Facts
- Translational data from Phase 1b/2 trial in relapsed/refractory multiple myeloma patients with median 4 prior lines of therapy
- Data show enhanced antigen-presenting activity, increased apoptotic signaling, and expansion of CD8 effector memory T cells
- Clinical responders had greater CD8 EM T cell expansion and lower T cell exhaustion vs non-responders
- Data to be presented at ASH annual meeting on December 12, 2026 (abstract #2183)
- Pelareorep has Fast Track designation for colorectal, anal, and pancreatic cancer but not for multiple myeloma
Financial Impact
No financial figures stated; early-stage translational data with no revenue or cost implications disclosed
Risk Factors
- Early-stage translational data may not translate to clinical benefit in larger trials
- No regulatory milestone or approval decision; multiple myeloma is not a Fast Track indication for pelareorep
- Company is clinical-stage with no approved products; relies on partnerships and capital markets for funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398560 |
Track record
32 reports on ONCY
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Viewing Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers